Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Sell Lab Workstations Business

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market on Thursday that it intends to sell its laboratory workstations business within the next 12 months.

In a document filed with the US Securities and Exchange Commission, the company said that senior management had made the decision to sell the "non-core" business on June 22. The laboratory workstation business is part of Thermo Fisher's Laboratory Products and Services Segment, and in 2011 it had revenues of $180 million and an operating loss of about $6 million, net of restructuring costs of $4 million.

Thermo Fisher will report the financial results for the business as discontinued operations beginning in the second quarter of 2012. During the quarter, it expects to record an after-tax charge of $50 million as the estimated loss on the planned sale.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.